Eli Lilly and Company (NYSE:LLY) Stock Holdings Lowered by Oxinas Partners Wealth Management LLC

Oxinas Partners Wealth Management LLC lowered its position in shares of Eli Lilly and Company (NYSE:LLYFree Report) by 8.6% in the 3rd quarter, according to its most recent disclosure with the SEC. The fund owned 488 shares of the company’s stock after selling 46 shares during the period. Oxinas Partners Wealth Management LLC’s holdings in Eli Lilly and Company were worth $433,000 as of its most recent filing with the SEC.

Other institutional investors have also modified their holdings of the company. Lynx Investment Advisory bought a new position in shares of Eli Lilly and Company during the second quarter worth about $32,000. LGT Financial Advisors LLC bought a new position in Eli Lilly and Company in the 2nd quarter valued at about $36,000. Cedar Mountain Advisors LLC grew its position in Eli Lilly and Company by 53.3% in the 3rd quarter. Cedar Mountain Advisors LLC now owns 46 shares of the company’s stock valued at $41,000 after buying an additional 16 shares in the last quarter. Morton Brown Family Wealth LLC grew its position in Eli Lilly and Company by 45.5% in the 2nd quarter. Morton Brown Family Wealth LLC now owns 48 shares of the company’s stock valued at $41,000 after buying an additional 15 shares in the last quarter. Finally, Unique Wealth Strategies LLC bought a new position in Eli Lilly and Company in the 2nd quarter valued at about $45,000. Institutional investors own 82.53% of the company’s stock.

Analyst Ratings Changes

LLY has been the subject of a number of recent analyst reports. Truist Financial increased their target price on shares of Eli Lilly and Company from $1,000.00 to $1,033.00 and gave the company a “buy” rating in a research report on Thursday, October 10th. BMO Capital Markets upped their price target on shares of Eli Lilly and Company from $1,001.00 to $1,101.00 and gave the company an “outperform” rating in a report on Friday, August 9th. Evercore ISI raised shares of Eli Lilly and Company to a “hold” rating in a report on Thursday, September 5th. Barclays upped their price target on shares of Eli Lilly and Company from $913.00 to $1,025.00 and gave the company an “overweight” rating in a report on Wednesday, July 10th. Finally, Berenberg Bank upped their price target on shares of Eli Lilly and Company from $1,000.00 to $1,050.00 and gave the company a “buy” rating in a report on Wednesday, August 14th. Three research analysts have rated the stock with a hold rating and seventeen have given a buy rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average target price of $979.29.

Read Our Latest Stock Report on LLY

Eli Lilly and Company Stock Down 1.7 %

Shares of LLY stock traded down $15.66 during trading on Tuesday, hitting $913.85. 2,282,406 shares of the company were exchanged, compared to its average volume of 2,998,564. The company has a debt-to-equity ratio of 1.74, a quick ratio of 0.87 and a current ratio of 1.11. The firm has a market capitalization of $868.53 billion, a price-to-earnings ratio of 134.14, a P/E/G ratio of 2.79 and a beta of 0.42. The business’s 50-day simple moving average is $913.95 and its 200 day simple moving average is $854.46. Eli Lilly and Company has a twelve month low of $547.61 and a twelve month high of $972.53.

Eli Lilly and Company (NYSE:LLYGet Free Report) last issued its quarterly earnings data on Thursday, August 8th. The company reported $3.92 earnings per share for the quarter, beating the consensus estimate of $2.64 by $1.28. The firm had revenue of $11.30 billion for the quarter, compared to analyst estimates of $9.83 billion. Eli Lilly and Company had a net margin of 18.86% and a return on equity of 67.52%. As a group, analysts forecast that Eli Lilly and Company will post 16.49 EPS for the current fiscal year.

Eli Lilly and Company Profile

(Free Report)

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.

Featured Stories

Want to see what other hedge funds are holding LLY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eli Lilly and Company (NYSE:LLYFree Report).

Institutional Ownership by Quarter for Eli Lilly and Company (NYSE:LLY)

Receive News & Ratings for Eli Lilly and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and Company and related companies with MarketBeat.com's FREE daily email newsletter.